HIV Glasgow 2018

aidsmap news from HIV Glasgow 2018

• High prevalence of diabetes and pre-diabetes in people at London HIV clinics

  Diabetes
  Keith Alcorn | 30 November 2018

  Around a third of people living with HIV receiving care at three large HIV clinics in south London had diabetes or pre-diabetes, while a Liverpool HIV clinic found that 70% of patients ...

• How has Glasgow responded to an outbreak of HIV among people who inject drugs?

  People who inject drugs
  Keith Alcorn | 07 November 2018

  Intensive efforts to reach people who inject drugs who have acquired HIV in a recent transmission outbreak in the city have resulted in high levels of antiretroviral treatment and viral suppression in ...

• Fostemsavir, novel gp120 inhibitor, salvages nearly half of people with no other treatment options left

  New and experimental HIV treatments
  Gus Cairns | 07 November 2018

  The recent International Congress on Drug Therapy in HIV Infection (HIV Glasgow) featured trials of several HIV drugs with modes of action different from the usual classes. Despite the overall success of ...

• Prolonged HIV suppression is possible using ibalizumab, analysis of highly drug-resistant people shows

  Treatment-experienced people
  Keith Alcorn | 02 November 2018

  A treatment regimen containing ibalizumab (Trogarzo), a monoclonal antibody designed to block HIV, led to substantial viral load reductions in a majority of highly treatment-experienced people with few treatment options left, Dr ...

• How safe is PrEP? Meta-analysis finds no increased risk of serious side-effects

  PrEP science
  Gus Cairns | 02 November 2018

  A meta-analysis of randomised controlled trials of tenofovir or tenofovir/emtricitabine as pre-exposure prophylaxis (PrEP) has found no increase in the risk of serious adverse health events over placebo. In particular, ...

• Hepatitis C increases the risk of premature delivery for pregnant women with HIV

  Child developmental issues
  Keith Alcorn | 02 November 2018

  Co-infection with hepatitis C greatly increases the risk of pre-term delivery for pregnant women with HIV, Polish researchers reported this week at the International Congress on Drug Therapy in HIV Infection (HIV ...

• Dolutegravir or lower-dose efavirenz equally effective, but less resistance with dolutegravir

  Starting treatment
  Keith Alcorn | 01 November 2018

  Dolutegravir-based treatment was no more effective than treatment based on a 400mg dose of efavirenz, a randomised trial conducted in Cameroon has found. However, almost half of people with very high viral ...

• Bictegravir matches dolutegravir in first-line treatment

  Starting treatment
  Keith Alcorn | 31 October 2018

  A triple combination containing the new integrase inhibitor bictegravir proved just as effective as a dolutegravir-based combination in suppressing viral load over 96 weeks, but people taking bictegravir experienced significantly fewer adverse events related ...

• Neural tube defects and integrase inhibitors: studies show no further evidence of increased risk

  Child developmental issues
  Keith Alcorn | 30 October 2018

  No further evidence of an increased risk of infant neural tube defects related to the use of dolutegravir or other integrase inhibitors in early pregnancy has emerged in safety reviews conducted over the ...

• Two-drug protease inhibitor treatment as effective as three-drug treatment – and fewer stop due to side-effects

  Treatment simplification strategies
  Keith Alcorn | 30 October 2018

  Antiretroviral treatment with a boosted protease inhibitor and one other drug is just as effective as three-drug antiretroviral therapy containing a boosted protease inhibitor but results in fewer treatment discontinuations due to side-effects, ...

• Generic PrEP bought online has correct amounts of emtricitabine and tenofovir

  Generic medicines
  Michael Carter | 28 October 2018

  People buying generic PrEP (pre-exposure prophylaxis) online can be confident they are buying the real thing, according to research presented to the International Congress on Drug Therapy in HIV Infection (HIV Glasgow) ...